Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by bball67on Jun 16, 2022 7:19am
162 Views
Post# 34760486

RE:RE:Strong Buy

RE:RE:Strong BuyWe have our deal, funding from the Boston Group through the start of human dosage. They have deep pockets and one of them is involved on a nearly daily basis with Promis to ensure progress toward the goals.It is a simple story of execution from here. Get the consolidation of shares done and get a US  stock listing, make a filing for human clinical trials of PMN 310 then begin human dosage.

Think about it, we are partnered with an amazing and successful group of business people who have an interest in ALZ, one of them founded the Alzheimer's Fund. They did their due diligence. Ask yourself, does this stock stay stuck at a $40M market cap through a bunch of good news through the beginning of human clinical trials or does it take off. The shares are going to be shrunk by a factor of 60, less supply. The market will be completely opened up to US institutional investors. Think about the risk and reward of owning this stock for another eight months. 
<< Previous
Bullboard Posts
Next >>